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Abstract Insulin receptor substrate p53 (IRSp53) is a key
player in cytoskeletal dynamics, interacting with the actin mod-
ulators WAVE2 and Mena. Here, we identi¢ed a PDZ protein,
MALS, as an IRSp53-interacting protein using a yeast two-
hybrid screen. A pull-down assay showed that IRSp53 and
MALS interact through the PDZ domain of MALS and the
C-terminal PDZ-binding sequence of IRSp53. Their interaction
in MDCK cells was also demonstrated by co-immunoprecipi-
tation. Immunocytochemistry showed the colocalization of
IRSp53 and MALS at cell^cell contacts. Cytochalasin D in-
duced the redistribution of both proteins to the cytosol. Thus,
MALS is a partner of IRSp53 anchoring the actin-based mem-
brane cytoskeleton at cell^cell contacts.
2 2003 Federation of European Biochemical Societies. Pub-
lished by Elsevier B.V. All rights reserved.
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1. Introduction
Insulin receptor substrate p53 (IRSp53) was originally iden-
ti¢ed as an insulin/insulin-like growth factor stimulation-de-
pendent tyrosine-phosphorylated protein in CHO cells and as
one of the postsynaptic density (PSD) components. [1,2]. This
protein di¡ers from other insulin receptor substrate (IRS)
family members in its conserved domain structure [3]. Four
isoforms of IRSp53 (IRSp53L, S, T, and IRS-58) have been
identi¢ed; each is composed of a common N-terminal portion
(amino acids 1^511) containing several protein^protein-inter-
acting domains and a short, unique C-terminal region [4].
Although di¡erent tissue distributions and phosphorylation
among the L, S, and T isoforms have been reported [4],
how their functions di¡er remains unknown. One recent study
demonstrated the involvement of IRSp53 in actin reorganiza-
tion. When Rac interacts with the N-terminus of IRSp53, the
src homology 3 (SH3) domain of IRSp53 binds to WAVE2,
resulting in the synergistic promotion of membrane ru¥ing
[5]. Cdc42 also binds to part of the CRIB (Cdc42/Rac-inter-
active binding) domain of IRSp53, inducing the interaction of
the SH3 domain of IRSp53 with Mena (an Ena/VASP family
member), followed by the activation of F-actin-enriched ¢lo-
podial and neurite extensions [6,7].
Here, we used a yeast two-hybrid screen to identify the
mammalian Lin-7 homologue MALS/Velis as an IRSp53S-
interacting protein, and demonstrated a direct interaction be-
tween these proteins by in vitro binding assays. Further, we
demonstrated a physiological interaction between these two
proteins in the actin-based membrane cytoskeleton at cell^
cell contacts between MDCK cells, by co-immunoprecipita-
tion and immunocytochemistry.
2. Materials and methods
2.1. Plasmid construction
Rat IRSp53S cDNA (NM_057196) was ampli¢ed by reverse tran-
scription-polymerase chain reaction (RT-PCR) and ligated into the
pcDNA3.1(+)-FLAG vector (Invitrogen). The cDNA encoding amino
acid (aa) residues 1^460 of IRSp53S was ampli¢ed by PCR and li-
gated into pGEX6P2 (Amersham Pharmacia Biotech). The cDNA
encoding the full-length (aa 1^207) rat MALS2 obtained by a yeast
two-hybrid screen was subcloned into pGEX6P3. The truncated mu-
tants of IRSp53S and MALS2 (Fig. 1) were ampli¢ed by PCR and
ligated into pGEX6P2 or pcDNA3.1(+)-FLAG vectors, respectively.
All constructs were sequenced using a 310 Genetic Analyzer (ABI
Prism).
2.2. Cell culture and transfection
COS7 and MDCK cells were cultured in Dulbecco’s modi¢ed Ea-
gle’s medium supplemented with 10% fetal calf serum. COS7 cells
were transfected using TransIT-LT1 (Mirus). For biochemical analy-
ses, COS7 cells were harvested 36 h after transfection.
2.3. Antibody production
Polyclonal antibodies against IRSp53 and MALS were produced as
follows: glutathione S-transferase (GST)-fused IRSp53 (aa 1^460)
and MALS2 (aa 1^207) expressed in Escherichia coli BL21 were pu-
ri¢ed using a glutathione-conjugated Sepharose 4B column (Amer-
sham Pharmacia Biotech), and were used for immunization into
New Zealand White rabbits. Antisera were preabsorbed with GST
protein, followed by puri¢cation using a GST-fused IRSp53 or
MALS2-coupled Sepharose 4B gel matrix, respectively.
2.4. Yeast two-hybrid screens
Rat IRSp53S cDNA (encoding aa 19^522) was fused to the LexA
DNA-binding domain using the pBTM116 vector. IRSp53S bait plas-
mid was used to screen a rat brain cDNA library cloned into the
pACT2 vector (Clontech). To select the putative interacting proteins,
yeast strain L40 transformed by the bait plasmid and the cDNA
library was grown on a yeast selection plate containing 5 mM
3-aminotriazole and lacking tryptophan, leucine, and histidine. The
acquired colonies were tested for L-galactosidase activity. The library
plasmids obtained by this screening were recovered through E. coli
transformation. The insert DNA in the positive clones was sequenced.
2.5. Immunocytochemistry
MDCK cells cultured on coverslips were ¢xed in 3.7% formalde-
hyde for 20 min, then permeabilized with 0.25% Triton X-100, and
incubated in blocking solution containing 5% normal goat serum, 1%
bovine serum albumin, and 0.05% Triton X-100 in phosphate-bu¡ered
saline minus (PBS) for 30 min. The following primary antibodies were
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incubated overnight in blocking solution: anti-IRSp53 or -MALS
polyclonal antibody (1:200) and anti-L-catenin (clone 14, Transduc-
tion Laboratories) monoclonal antibody (1:500). F-actin was labeled
with Alexa Fluor1 568-phalloidin. Subsequently, the cells were la-
beled with Alexa Fluor1 488-conjugated anti-rabbit and 546-conju-
gated anti-mouse secondary antibodies (2 Wg/ml, Molecular Probes) in
the blocking solution for 40 min. After being washed with PBS, the
coverslips were mounted onto glass slides using a Prolong Antifade
Kit (Molecular Probes). Where indicated, the cells were extracted with
Triton X-100 bu¡er (50 mM NaCl, 10 mM PIPES pH 6.8, 3 mM
MgCl2, 0.5% Triton X-100, and 300 mM sucrose) on ice for 10 min
before ¢xation [8]. The confocal images were obtained using a Zeiss
410 confocal laser scanning microscope.
2.6. Biochemical analysis
All procedures were performed at 4‡C. For the pull-down assay,
transfected COS7 cells were lysed in bu¡er (25 mM Tris^HCl pH 7.5,
150 mM NaCl, 1 mM EDTA, 1% Triton X-100, and a cocktail of
protease inhibitors). After centrifugation at 15 000Ug for 20 min, the
supernatant was incubated with control (GST) or GST-fused MALS2
with glutathione-Sepharose 4B beads for 3 h. After being washed with
lysis bu¡er, the proteins bound to Sepharose beads were solubilized
with sodium dodecyl sulfate (SDS) sample bu¡er. For co-immunopre-
cipitation, MDCK cells were homogenized in solubilization bu¡er (25
mM Tris^HCl pH 7.5, 100 mM NaCl, 1 mM MgCl2, 1% Triton
X-100, and a cocktail of protease inhibitors) for 30 min. After cen-
trifugation, the supernatant was incubated with anti-MALS antibody
(5 Wg)-conjugated Sepharose 4B (Amersham Pharmacia Biotech) for
4 h. After being washed with solubilization bu¡er, the proteins bound
to Sepharose beads were solubilized with SDS sample bu¡er, sepa-
rated by SDS^polyacrylamide gel electrophoresis, and transferred to
nitrocellulose membranes. Anti-IRSp53 (1:5000), -MALS (1:5000),
and -FLAG (1:2000, IBI-Kodak) antibodies were used as the primary
antibodies and visualized using peroxidase-conjugated secondary anti-
bodies followed by ECL (Amersham Pharmacia). For the preabsorp-
tion of antibodies, the diluted anti-IRSp53 and -MALS antibodies
were preincubated with excess amounts of GST-IRSp53 and GST-
MALS, respectively.
2.7. cDNA cloning
A cDNA library was constructed from MDCK cells using a ZAP
Express1 cDNA synthesis kit (Stratagene). Approximately 1U105
plaques of a cDNA library were screened using a 32P-labeled probe
encoding the open reading frame of rat IRSp53 cDNA.
3. Results
We isolated IRSp53S using a PSD protein-speci¢c mono-
clonal antibody (149H) that recognizes the 58/53-kDa protein
(unpublished data). To isolate an IRSp53-interacting protein,
we performed a yeast two-hybrid screen using rat IRSp53S
(aa 19^522) as bait. Among V1.1U106 clones of a rat brain
cDNA library, 17 candidates were isolated (Table 1). Many of
them had at least one PSD-95/Disc large/ZO-1 homology
(PDZ) domain [9]. We noted the presence of a PDZ-bind-
ing-like sequence (S-T-V) at the C-terminal end of IRSp53S.
This sequence is conserved among rat (NM_057196), mouse
(AAK68153), dog (cloned in this study, AB112349), and hu-
man (BAA36586) homologs.
To examine the interaction between IRSp53S and MALS2/
Veli-2, which was represented by a large number of the iso-
lated clones, we performed a pull-down assay with GST or
GST-MALS2 in extracts from COS7 cells transfected with
FLAG-tagged IRSp53S wild type or IRSp53S lacking the
C-terminal PDZ-binding sequence (FLAG-IRSp53SvPDZ-
BS) (Fig. 1). FLAG-IRSp53S bound to GST-MALS2, but
FLAG-IRSp53SvPDZ-BS did not (lanes 1^3 in Fig. 2). Fur-
ther, the PDZ domain of MALS2 (GST-MALS2[C]) bound to
FLAG-IRSp53S, but the N-terminal region of MALS2 (GST-
MALS[N]) did not (lanes 4 and 5 in Fig. 2). These results
indicate that IRSp53S directly interacts with the PDZ domain
of MALS via its C-terminal PDZ-binding sequence.
It has been reported that MALS1 and 2 are speci¢cally
Fig. 1. Schematic diagrams of the IRSp53S and MALS domain structures. IRSp53 contains several protein^protein-interaction domains: from
the N-terminus, a partial CRIB domain, SH3-binding domain, SH3 domain, WW-binding domain, and putative PDZ-binding sequence at the
C-terminal end. MALS2 has a unique N-terminal sequence followed by a PDZ domain that is highly homologous among the MALS family
members. The truncated mutants used in this experiment are also shown.
Fig. 2. In vitro interaction of IRSp53S with MALS2. COS7 cells
were transfected with expression vectors encoding FLAG-IRSp53S
wild type (lanes 1,2,4,5) or FLAG-IRSp53SvPDZ-BS (lane 3). The
cell extracts were pulled down with GST alone (lane 1), GST-
MALS2[wt] (lanes 2,3), or truncated mutants GST-MALS2[N] (lane
4), or GST-MALS2[C] (lane 5). The proteins that bound to the
above ligands were analyzed by Western blotting.
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expressed in the brain, whereas MALS3 is widely distributed
in the brain, kidney, liver, and MDCK cells [10,11], and that
MALS proteins localize to the cell^cell contacts of MDCK
cells [8]. Western blotting revealed that the anti-MALS anti-
body recognized the two bands with apparent molecular
masses of 23 kDa (MALS2/3) and 30 kDa (MALS1) in the
rat brain lysates, indicating that this antibody cross-reacts
with all MALS isoforms (lane 3 in Fig. 3A). The anti-
IRSp53 antibody recognizes all IRSp53 isoforms. Using our
anti-IRSp53 and -MALS antibodies, we detected IRSp53 and
MALS (MALS2/3) proteins with the expected mobilities in
MDCK cell lysates (lanes 1 and 4 in Fig. 3A). Further, these
bands were not observed when the antibodies were preab-
sorbed with their respective antigens (lanes 2 and 5 in Fig.
3A). Taking together our present and other data [11], MALS3
is considered to be the major isoform in MDCK cells. To
con¢rm the presence of the IRSp53S homologue in MDCK
cells, a cDNA library constructed from MDCK cells was
screened using the full-length rat IRSp53S cDNA as a probe.
Among ¢ve positive clones isolated, four clones encoded
IRSp53S containing the PDZ-binding sequence, and one en-
coded an IRSp53T homologue lacking the PDZ-binding se-
quence. To verify the interaction between IRSp53 and MALS
in vivo, we performed co-immunoprecipitation assays. Immu-
noprecipitation of extracts from con£uent MDCK cells with
the anti-MALS antibody, but not with non-immune IgG, re-
sulted in the co-precipitation of IRSp53 (Fig. 3B).
We next examined the immunolocalization of IRSp53 and
MALS in MDCK cells. MALS was predominantly localized
to cell^cell contacts, where they were co-localized with L-cat-
enin (Fig. 4B). Although IRSp53 was more di¡use than
MALS in the cytoplasm, it was co-localized with L-catenin
at cell^cell contacts (Fig. 4A), where it also co-localized
with the actin-based membrane cytoskeleton, which stained
with £uorescence-labeled phalloidin at cell^cell contacts (Fig.
4C) [12]. To con¢rm whether IRSp53 was linked to the cyto-
skeletal fraction at cell^cell contacts, we performed in situ
extraction with Triton X-100. When MDCK cells were ex-
tracted with 0.5% Triton X-100 before ¢xation, the cytosolic
IRSp53 staining was lost without a¡ecting its localization at
cell^cell contacts (Fig. 5B). Treatment with the actin-depoly-
merizing reagent cytochalasin D induced the redistribution of
IRSp53, MALS, and F-actin from the cell^cell contacts to the
cytosolic puncta (Fig. 5B, cytochalasin D). These results sug-
gested that IRSp53 is linked to the actin-based membrane
cytoskeleton.
4. Discussion
In this study, we demonstrated by in vitro binding assays
that IRSp53S directly interacts with the PDZ domain of
Table 1
The candidates for IRSp53-interacting proteins
Protein Number of positive clones Propertiesa Reference
Lin7-A (MALS2) 7 PDZ, TMb, Tr [13]
SAP102 4 PDZ, SH3, RC, TMb [22]
Eps8 2 SH3 [23]
NIL-16 1 PDZ, TM [24]
MAGI-1 1 PDZ [25]
S-SCAML 1 PDZ, TMb [26]
SAP97 1 PDZ, SH3, RC, TMb [27]
aTM, transmembrane domain; TMb, transmembrane-binding protein; RC, receptor clustering; Tr, involved in tra⁄cking.
Fig. 3. IRSp53 interacts with MALS in MDCK cells. A: MDCK
cell lysates (lanes 1,2,4,5: 20 Wg protein) or whole rat brain lysates
(lane 3: 20 Wg protein) were probed with anti-IRSp53 (lane 1) and
-MALS (lanes 3,4) antibodies, or the same antibodies preabsorbed
with GST-IRSp53 (lane 2) or GST-MALS2 (lane 5). B: In vivo im-
munoprecipitation from MDCK cell extracts. The extracts were im-
munoprecipitated with anti-MALS- or preimmune control IgG-con-
jugated Sepharose 4B (IP). The immunoprecipitates were blotted
with the indicated antibodies (IB).
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MALS via its C-terminal PDZ-binding sequence. Jo et al. [10]
reported that the PDZ domain of MALS selectively associates
with peptides terminating in E-T/S-R/X-V/I/L, by a⁄nity pan-
ning using a random peptide library. Indeed, several MALS-
interacting proteins, such as the NR2 subunit of N-methyl-D-
aspartate (NMDA) receptors and LET-23, a receptor tyrosine
kinase in Caenorhabditis elegans, contain this sequence. Three
of the C-terminal residues of IRSp53S ¢t this sequence, but
the fourth amino acid is not glutamate but valine (Fig. 1).
Thus, the interaction between IRSp53 and MALS is an ex-
ception to this rule, along with the MALS/L-catenin interac-
tion. The C-terminal end of L-catenin is D-T-D-L [8]. We also
demonstrated the interaction between IRSp53 and MALS in
MDCK cells by co-immunoprecipitation (Fig. 3). MALS1 and
2 are speci¢cally expressed in the brain, whereas MALS3 is
expressed in the brain and other, peripheral tissues [10]. The
amino acid sequences among the MALS family members are
highly conserved (85.7% homology between MALS2 and 3 of
total residues, and 95.4% between the PDZ domains of
MALS2 and 3), suggesting an interaction between IRSp53S
and MALS isoforms is possible.
Confocal imaging analysis showed that IRSp53 and MALS
are co-localized at cell^cell contacts of MDCK cells (Fig. 4).
In polarized MDCK cells, the IRSp53 at cell^cell contacts was
resistant to non-ionic detergent, and treatment with cytocha-
lasin D induced the translocation of IRSp53 from the cell^cell
contacts to the cytoplasmic puncta, indicating that IRSp53 is
Fig. 4. The localization of IRSp53 and MALS in MDCK cells. MDCK cells were stained with anti-IRSp53 (A,C, green) or anti-MALS
(B, green) antibodies. The localization of IRSp53 and MALS was compared with the cell junction marker, L-catenin (A,B, red) or F-actin
stained with £uorescence-labeled phalloidin (C, red). Bar, 15 Wm.
6
Fig. 5. IRSp53 links to the actin-based membrane cytoskeleton.
A: MDCK cells were ¢xed without treatment (a,b) or pretreated
with extraction bu¡er before ¢xation (c^f). The ¢xed cells were co-
immunostained with anti-IRSp53 (a,c,e) and anti-L-catenin (b,d) or
phalloidin (f). B: MDCK cells were incubated with (c,cP,d,dP) or
without (a,aP,b,bP) 2 WM cytochalasin D for 2 h. After ¢xation, the
cells were immunolabeled with anti-IRSp53 (a,c; green) or anti-
MALS (b,d) antibodies. F-actin was visualized with £uorescence-la-
beled phalloidin (aP^dP ; red). Bar, 15 Wm.
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a component of the actin-based membrane cytoskeleton (Fig.
5). Strong cell^cell contact requires a linkage between cadher-
in and the actin cytoskeleton via catenins [13,14]. In addition,
members of the Rho family of small G proteins (Rho, Rac1,
and Cdc42) and VASP/Mena have been demonstrated to reg-
ulate adherens junction formation in MDCK cells and pri-
mary epidermal keratinocytes [15^18]. Thus, IRSp53 may
work together with its interacting partners in the formation
or maintenance of the adhesion structures of epithelial cells. It
has been demonstrated that MALS/Lin-7 interacts with sev-
eral proteins, including the NR2B subunit of the NMDA
receptor, L-catenin, BGT-1, LET-23, Pals, and VAM-1, and
carries them to appropriate sites such as cell^cell contacts of
epithelial cells or synaptic sites of neurons [8,10,19^21]. Thus,
MALS may play a role in translocating IRSp53S to or an-
choring it at the cell^cell contacts of epithelial cells.
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